Search

everythinglearnresearchcommunity

for

Search:↓

A user is starting a hair loss treatment with a 3-in-1 spray containing finasteride, minoxidil, and tretinoin. They are concerned about whether to continue shaving their head and how to determine if hair follicles are dead.

The user experienced significant hair maintenance using 0.25mg daily finasteride and minoxidil foam, with minimal side effects. They recommend oral finasteride for better results, especially for the crown area.

User shares 4-month progress using finasteride, minoxidil, and microneedling for hair loss. Others discuss body hair, hair transplant possibilities, and user's treatment response.

User has been using minoxidil 6%, finasteride 0.3%, tretinoin 0.025%, and microneedling twice a week for 2.5 months. They are considering switching to oral treatments.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

A user's 7-month progress using 1 mg finasteride and topical minoxidil, with no side effects from the finasteride, achieving baby hairs on the hairline and other positive results. Other users have discussed different treatments such as microneedling and supplements, providing advice and encouragement to the poster.

A 37-year-old male shared his 3-month progress using oral finasteride, oral minoxidil, and microneedling for hair loss, showing significant improvement. He experienced initial side effects like anxiety, low mood, and testicular ache.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.